Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (NASDAQ:PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.
AMD, Samsung’s Warnings Underline Looming Tech Slowdown — But This Analyst Sees Pockets Of Strength
Advanced Micro Devices Inc. (NASDAQ: AMD) shares moved sharply to the downside in after-hours trading on Thursday after the chipmaker warned of a revenue shortfall.
